Developmental Projects and Trans-Alliance Activities

虽然各个项目以及整个中心的目的和目标都非常明确，但通常的研究流程，特别是在采取如此广泛的方法并有多个协调小组参与的情况下，肯定会产生一些重要的问题，这些问题必须为整个项目的成功作出回答，但在最初的个别项目的目标中没有涉及到。在这种情况下，我们将启动特定的短期(从6个月到一年)试点项目，以竞争性的方式在中心的一个组成部分内执行，因为这将涉及额外的资金。 内部执行委员会应在外部咨询委员会的协助下，通过讨论中心的需要，明确确定对这类项目的需要。一旦明确确定了这种试点项目的需要，就将向所有项目负责人通报这一需要，并给予他们很短但足够的时间(2至4周)提交他们的提案(2至3页)和适当的预算。在接下来的两周内，执行委员会将与咨询委员会一起作出决定，最佳提案将由一笔预留资金提供资金(应国家投资委员会的要求)。 这种试点项目MAV的假设例子包括： ？如果最初选择的纳米载体不符合最初的期望，则开发和测试新型纳米载体； 开发和测试一种新的加载程序，如果最初使用的加载程序提供的药物负载低于最佳载药量； ？在最初建议的另一个动物模型中测试某种纳米修复，如果最初的 暗示一个人无论出于什么原因都表现得不够好； ？需要根据纳米表征和/或成像岩芯的数据开发任何替代方法； ？需要进行额外的研究，这可能源于任何最新的文献数据，以根据最新获得的科学信息调整中心的项目。 这种试点项目也可以作为一种机制，让主办机构的新初级科学家参与中心的活动。 跨联盟活动(挑战项目)。 可以很容易地预见，积极开展CCNE将产生新的知识和想法，而在东道主CCNE的框架内，这些知识和想法的全面使用和/或实施将不完全可能。在这种情况下，自然发展是在不同的CCNE之间建立工作联系和联合项目，以解决这些问题并快速有效地响应出现的需求。 显然，在这种情况下，所有CCNE都应该了解他们同行的独特能力，以帮助他们选择合适的合作伙伴。这类信息应通过相应的生物信息学单位或核心传播。 我们建议的未来转化性癌症纳米医学中心的独特能力包括： 1.我们成像核心的优良设施和广泛经验(见中心组织部分以及具体的成像核心描述中的详细核心描述)，可用于各种联合项目； 2.GMP扩大规模和制造设施的参与(参见中心组织部分以及具体制造核心描述中的详细核心描述)，如果其他CCNE将需要测试其候选药物的工业扩大和制造的可能性，可用于各种联合项目。 因此，拟议的转化型癌症纳米医学中心将能够跨联盟 通过使用尖端成像技术研究各种纳米药物的生物行为，开发用于癌症的新型成像试剂，以及为具有良好临床前景的各种纳米药物制定工业化生产计划。

Although, the aims and goals of the individual projects as well as of the Center as a whole are quite clear, the usual flow of research, especially, with such a broad approach and with the involvement of multiple coordinated groups, will certainly generate some important questions, which have to answered for the success of the whole project, but were not addressed in the aims of the initial individual projects. In such cases, we will initiate specific short term (from 6 months to a year) Pilot Projects to be performed within one of Center's component on a competitive basis, since this will be involving an additional funding. The need for such projects should be cleariy established by discussing the needs of the Center by the Internal Executive Committee with the assistance of the External Advisory Board. As soon as the need for such Pilot Project is cleariy established, all individual project leaders will be informed about such a need and given with short but sufficient time (from 2 to 4 weeks) to submit their proposal (2-to-3 pages long) and appropriate budgets. Within the next two weeks the decision will be made by the Executive Committee together with the Advisory Board and the best proposal will be funded from a set aside funds (as requested by the NCI). Hypothetical examples of such Pilot Proiects mav include: ¿ Development and testing new type of a nanocarrier if the initially selected one does not meet the initial expectation; ¿ Development and testing a novel loading procedure if the initially used one provides less than optimal drug load; ¿ Testing of a certain nanopreparation in another animal model than initially suggested, if the initially suggested one does not perform good enough for whatever reason; ¿ Need to develop any alternative approach based on the data from Nanocharacterization and/or Imaging Cores; ¿ Need to make an additional research, which can arise from any recent literature data to adjust Center's projects according to newly available scientific information. Such Pilot Project can also serve as a mechanism to involve new junior scientists from the host institutions in the Center's activities. Trans-Alliance activities (Challenge projects). One can easily foresee that actively working CCNE will be generating new knowledge and ideas, the full scale use and/or implementation of which will not be entirely possible within the frame of the host CCNE. Natural development in this case is the creation of working connections and joint projects between different CCNEs to address such issues and respond the arising need fast and effectively. Clearly, in this case all CCNEs should about the unique capabilities of their peers to help with be infonned choosing a proper partner. This type of the information should be disseminated via the corresponding Bioinformatics Units or Cores. The unique capabilities of the future Center for Translational Cancer Nanomedicine suggested by us include: 1. Excellent facilities and broad experience of our Imaging Core (see the detailed Core description in the Center Organization Section as well as in the specific Imaging Core description), which could be used for various joint projects; 2. The involvement of the GMP Scaling Up and Manufacturing facility (see the detailed Core description in the Center Organization Section as well as in the specific Manufacturing Core description), which can be used for various joint projects if other CCNEs will need to test the possibilities of industrial scaling up and manufacturing of their drug candidates. Thus, the proposed Center for Translational Cancer Nanomedicine will be capable of Trans-Alliance collaboration on the study of the biological behavior of various nanomedicines by using a cutting edge imaging technologies, on the development of novel imaging agents for cancer, and on the development of industrial production schemes for a broad set of various nanomedicines with good clinical promise.